abstract |
The invention relates to the compounds of the formula <IMAGE> (I) wherein the C(=NH)-NHR3 group may be in tautomeric or isomeric form, and phamaceutically acceptable salts thereof. The compounds are useful as selective LTB4 receptor antagonists. |